We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+14.9%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$272M
AUM Growth
+$12.6M
Cap. Flow
-$13.6M
Cap. Flow %
-4.98%
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$4.13M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$2.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.07M
4
CLF icon
Cleveland-Cliffs
CLF
+$1.9M
5
FERG icon
Ferguson
FERG
+$1.82M

Top Sells

Rank Stock Value
1
ACI icon
Albertsons Companies
ACI
+$4.15M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3.03M
3
GEV icon
GE Vernova
GEV
+$2.41M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$2.1M
5
BHC icon
Bausch Health
BHC
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 37.62%
2 Technology 22.09%
3 Industrials 8.52%
4 Financials 6.08%
5 Consumer Discretionary 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
151
Bausch Health
BHC
$2.37B
– –
-217,600
Closed -$2.03M
BN icon
152
Brookfield
BN
$109B
– –
-40,800
Closed -$1.43M
CIEN icon
153
Ciena
CIEN
$54.9B
– –
-24,300
Closed -$1.47M
CRH icon
154
CRH
CRH
$66.9B
– –
-16,700
Closed -$1.47M
CRNX icon
155
Crinetics Pharmaceuticals
CRNX
$8.93B
– –
-28,911
Closed -$970K
DUOL icon
156
Duolingo
DUOL
$6.42B
– –
-4,200
Closed -$1.3M
ELV icon
157
Elevance Health
ELV
$86.2B
– –
-3,300
Closed -$1.44M
ERAS icon
158
Erasca
ERAS
$6.29B
– –
-135,667
Closed -$186K
EYE icon
159
National Vision
EYE
$1.8B
– –
-111,300
Closed -$1.42M
GEHC icon
160
GE HealthCare
GEHC
$32.9B
– –
-23,200
Closed -$1.87M
GOOG icon
161
Alphabet (Google) Class C
GOOG
$4.35T
– –
-13,436
Closed -$2.1M
KALV
162
DELISTED
KalVista Pharmaceuticals
KALV
– –
-33,305
Closed -$384K
KNSA icon
163
Kiniksa Pharmaceuticals
KNSA
$5.97B
– –
-74,639
Closed -$1.66M
KYMR icon
164
Kymera Therapeutics
KYMR
$9.03B
– –
-8,733
Closed -$239K
MIRM icon
165
Mirum Pharmaceuticals
MIRM
$6.02B
– –
-8,942
Closed -$403K
MRVL icon
166
Marvell Technology
MRVL
$187B
– –
-20,200
Closed -$1.24M
NATL icon
167
NCR Atleos
NATL
$3.43B
– –
-61,900
Closed -$1.63M
ON icon
168
ON Semiconductor
ON
$31.1B
– –
-31,400
Closed -$1.28M
PLRX icon
169
Pliant Therapeutics
PLRX
$64.4M
– –
-109,938
Closed -$148K
QSR icon
170
Restaurant Brands International
QSR
$25.4B
– –
-20,300
Closed -$1.35M
RARE icon
171
Ultragenyx Pharmaceutical
RARE
$2.64B
– –
-13,328
Closed -$483K
SRPT icon
172
Sarepta Therapeutics
SRPT
$1.81B
– –
-5,212
Closed -$333K
STZ icon
173
Constellation Brands
STZ
$22.8B
– –
-9,900
Closed -$1.82M
SWTX
174
DELISTED
SpringWorks Therapeutics
SWTX
– –
-68,758
Closed -$3.03M
TSM icon
175
TSMC
TSM
$2.17T
– –
-8,900
Closed -$1.48M
4 5 6
7
8

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2025 Portfolio in Review

As of Q2 2025, HighVista Strategies held 177 positions worth $272M, up 4.9% from $260M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $13.6M in Q2 2025, closing 31 positions and reducing 55 holdings. Its most notable exit was Albertsons Companies, an estimated $4.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Mineralys Therapeutics worth $2.03M.

  • HighVista Strategies's largest Q2 2025 buy was Mineralys Therapeutics: 150,138 shares worth $2.03M.
  • HighVista Strategies added most to Viridian Therapeutics in Q2 2025, an estimated $4.13M increase.
  • HighVista Strategies's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $2.41M.
  • HighVista Strategies fully exited Albertsons Companies in Q2 2025, selling an estimated $4.15M.
  • HighVista Strategies's ten largest holdings make up 27% of its $272M portfolio in Q2 2025.
  • HighVista Strategies opened 29 new positions and closed 31 in Q2 2025.
  • HighVista Strategies's portfolio value rose 4.9% quarter-over-quarter to $272M.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.